Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neural TherapeuticsXCNQ:NURL EBITDA Margin % is 0.00% as of Jan. 2026. The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, Neural Therapeutics ranks worse than 106382.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neural Therapeutics's EBITDA for the
three
months ended in Jan. 2026 was C$-0.11 Mil. Neural Therapeutics's Revenue for the
three
months ended in Jan. 2026 was C$0.00 Mil. Therefore, Neural Therapeutics's EBITDA margin for the quarter that ended in Jan. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neural Therapeutics EBITDA Margin % Related Terms
Neural Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neural Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:NURL vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Neural Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neural Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neural Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neural Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neural Therapeutics (XCNQ:NURL) has a EBITDA Margin % of 0.00% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry.
Is Neural Therapeutics' EBITDA Margin % too high?
Neural Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Neural Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neural Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #999999 out of 940 companies for EBITDA Margin %. This places Neural Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (XCNQ:NURL) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neural Therapeutics (XCNQ:NURL), the current EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:NURL has been successfully added to your 
